Cabalettabio.com

Cabaletta Bio Expands Scientific Regulatory, and Cell Therapy

web-- Carl June, M.D., who led discovery and development of the breakthrough CAR T platform at the University of Pennsylvania-- Jay Siegel, M.D., former head of …

Actived: 7 days ago

URL: https://www.cabalettabio.com/news-media/press-releases/detail/29/cabaletta-bio-expands-scientific-regulatory-and-cell

Cabaletta Bio Receives FDA Clearance of IND Application for …

web– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating …

Category:  Health Go Health

News & Events

webPHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and …

Category:  Health Go Health

News & Events

webPHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and …

Category:  Health Go Health

Management Team :: Cabaletta Bio, Inc. (CABA)

webDr. Nichtberger has served as Chief Executive Officer, President, and Chairman of Cabaletta Bio since its founding in 2017. He is also a senior fellow and adjunct professor at the …

Category:  Health Go Health

Cabaletta Bio Receives FDA Clearance of IND Application for CABA …

web– IND application cleared within 6 months of in-licensing CABA-201 binder – – CABA-201 data package and experience from prior autoimmune cell therapy INDs …

Category:  Health Go Health

Cabaletta Bio to Present at the American Society of Gene and Cell

webPHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the …

Category:  Health Go Health

Cabaletta Bio and Artisan Bio Announce Gene Editing Research …

webPHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on …

Category:  Health Go Health

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care

webPHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the …

Category:  Health Go Health

Cabaletta Bio Appoints Biopharmaceutical Leader Scott Brun, M.D.

webDr. Brun’s early and late-stage clinical development expertise in autoimmune, neurologic, and renal disease areas aligns well with Cabaletta’s rapidly emerging pipeline

Category:  Health Go Health

Cabaletta Bio Announces Presentation of Preclinical Data Showing

webMuSK-CAART is the second product candidate that has emerged from the Cabaletta Approach to selective B cell Ablation (CABA™) platform. The Company has …

Category:  Health Go Health

Cabaletta Bio Reports Acute Safety Data from the First Dose …

web– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 – – Second dose cohort to be initiated after the third …

Category:  Health Go Health

Cabaletta Bio Closes $50 Million Series B Financing to Establish

webDeerfield Management Company, Boxer Capital of Tavistock Group, Redmile Group and Cormorant Capital join founding investors Adage Capital, an undisclosed …

Category:  Health Go Health

Cabaletta Bio News and Events Cabaletta Bio, Inc. (CABA)

webOur RESET TM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus and myositis are now recruiting.

Category:  Health Go Health

Cabaletta Bio Board of Directors :: Cabaletta Bio, Inc. (CABA)

webCatherine Bollard, M.D. Independent Director, George Washington University. Dr. Bollard joined Cabaletta’s Board of Directors in April 2019. She is the director of the Center for …

Category:  Health Go Health

Cabaletta Bio Announces Expansion of Sponsored Research …

webCollaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases. PHILADELPHIA, May 28, 2020 …

Category:  Health Go Health

Scientific Advisory Board

webCabaletta Bio Scientific Advisory Board :: Cabaletta Bio, Inc. (CABA) Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus and myositis are …

Category:  Health Go Health

Cell Therapy Industry Pioneer, Gwendolyn Binder, Ph.D., to Join

webDr. Binder is an expert in T cell product development, translational research and GMP manufacturing. Joins Cabaletta Bio as Executive Vice President, Science & …

Category:  Health Go Health

Autoimmune Clinical Drug Development Expert

webAutoimmune Clinical Drug Development Expert, David J. Chang, M.D., M.P.H., Joins Cabaletta Bio as Chief Medical Officer

Category:  Medical Go Health